Advertisement

ABT

Abbott Laboratories

Healthcare · USD

Set alert

Price alert · ABT

All alert types
106.20 USD +1.63 +1.56%
As of Oct 30, 2026 Extended hours 106.25 +0.05%
Bid
106.19 × 400
Ask
106.27 × 100
104.60 Day range 106.85
82.56 52-week range 130.59
YTD
-15.24%
1 year
-14.82%
Open
106.15
Prev close
104.57
Mkt cap
184.98B
Vol
8.44M
Avg vol
8.76M
EPS
2.69
P/E
39.48
Div yield
2.41%
More statistics
Low
104.60
High
106.85
Forward P/E
17.89
Beta
0.58
Short ratio
1.84
Inst. own
81.90%
Dividend
2.52
Ex-div date
Oct 14, 2026
Earnings
Jan 28, 2027
50-d avg
104.50
200-d avg
101.79
1y target
118.52

MAX chart

Chart tools
Interval
ABT all-time price chart1.1236.571.9107.2142.6Dec 84Jun 93Sep 01Mar 10Jun 18Oct 26

Key statistics

Market cap
185.05B
Enterprise value
208.72B
Trailing P/E
39.49
Forward P/E
17.89
PEG ratio
1.49
Price / sales
3.84
Price / book
3.60
EPS (TTM)
2.69
Beta
0.58
Dividend yield
2.41%
Payout ratio
78.71%
Profit margin
9.75%
Revenue (TTM)
48.23B
Revenue growth
14.50%
Free cash flow
0
Total cash
5.60B
Total debt
32.72B
Return on equity
0.00%
Shares outstanding
1.74B
Short % of float
1.12%
50-day average
104.50
200-day average
101.79

Analyst view

Consensus: buy

Buy
Price target (mean) 118.52 +11.6% upside
Target (low)
100.00
Target (mean)
118.52
Target (high)
130.00
Ratings (0m) 28 23 buy · 5 hold · 0 sell
  • Strong buy5
  • Buy18
  • Hold5
  • Sell0
  • Strong sell0

Next earnings

Jan 28, 2027

Expected Jan 28, 2027. Consensus EPS estimate 1.64.

Earnings history

Financials — quick view

All financials
ABT Revenue — quarterly 12.59B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ABT Net income — quarterly 928.00M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ABT EPS — quarterly 0.53
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

ABT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Jan 28, 2027Dec 30, 20261.64———
Oct 21, 2026Sep 30, 20261.421.420.000.00%
Jul 16, 2026Jun 30, 20261.281.31+0.03+2.34%
Apr 16, 2026Mar 31, 20261.141.15+0.01+0.88%
Jan 22, 2026Dec 31, 20251.501.500.000.00%
Oct 15, 2025Sep 30, 20251.301.300.000.00%

Upgrades / downgrades

ABT analyst upgrades and downgrades
DateFirmActionFromTo
Oct 27, 2026Argus ResearchdownBuyHold
Oct 23, 2026Wells FargomainOverweightOverweight
Oct 22, 2026CitigroupmainBuyBuy
Oct 22, 2026RBC CapitalmainOutperformOutperform
Oct 22, 2026Wells FargomainOverweightOverweight
Oct 22, 2026JP MorganmainOverweightOverweight

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
abbott.com

News

Your note

Sign in to keep a note on ABT — it syncs with the Stock Master app.

Insider holders

ABT insider holders
InsiderRelationLatest transactionDateShares held
ALLEN HUBERT L.OfficerStock Award(Grant)Feb 24, 2025200,281
BOUDREAU PHILIP PChief Financial OfficerPurchaseApr 22, 20260
CONROY KEVIN TDirectorStock Award(Grant)Apr 23, 2026133,737
EARNHARDT LISA DOfficerStock Award(Grant)Feb 23, 202698,984
FORD ROBERT B.Chief Executive OfficerSaleAug 24, 2026522,664
MORELAND MARY KOfficerSaleMar 1, 2026116,136

Institution ownership

ABT institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.82%152,563,47616.21BJun 29, 2026
Vanguard Capital Management LLC6.57%113,750,99412.08BJun 29, 2026
State Street Corporation4.68%80,926,2348.60BJun 29, 2026
Charles Schwab Investment Management, Inc.3.45%59,674,5076.34BJun 29, 2026
Vanguard Portfolio Management LLC2.83%49,017,8665.21BJun 29, 2026
Geode Capital Management, LLC2.27%39,219,3374.17BJun 29, 2026

Fund ownership

ABT fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.20%55,297,2795.87BJun 29, 2026
SCHWAB STRATEGIC TRUST-Schwab US Dividend Equity ETF2.75%47,631,7455.06BAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.61%45,138,4904.80BJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%23,056,9072.45BSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.31%22,610,2902.40BAug 30, 2026
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust1.24%21,408,9182.27BSep 29, 2026
Advertisement